Friederike Sixel-Döring
Research Subjects
Friederike Sixel-Döring has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Abril Beatriz
University Hospital of Nîmes
5 shared publications - Alex Desautels
Centre d’Etudes Avancees en Medecine du Sommeil, CIUSSS-NIM - Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada
5 shared publications - Ambra Stefani
Department of Neurology Medical University Innsbruck Innsbruck Austria
5 shared publications - Anna Heidbreder
Johannes-Kepler-Universität Linz Unviversitätsklinik für Neurologie
5 shared publications - Birgit Högl
Neurology Department, Sleep Disorders Clinic Innsbruck Medical University Innsbruck Austria
5 shared publications - Bradley F. Boeve
Mayo Clinic Rochester
5 shared publications
Latest Publications
- 24 September 2021
- Published by Springer Nature in InFo Neurologie + Psychiatrie
- Vol. 23 (9) , 40-49
Parkinson-Therapie in der Pandemie
- 24 September 2021
- Published by Springer Nature in InFo Neurologie + Psychiatrie
- Vol. 23 (9) , 40-49
Parkinson-Therapie in der Pandemie
- Open Access
Novel associations of BST1 and LAMP3 with rapid eye movement sleep behavior disorder
Isolated rapid-eye-movement (REM) sleep behavior disorder (iRBD) is a parasomnia, characterized by loss of muscle atonia and dream enactment occurring during REM sleep phase. Since a large subgroup of iRBD patients will convert to Parkinson’s disease, and since previous genetic studies have suggested common genes, it is likely that there is at least a partial overlap between iRBD and Parkinson’s disease genetics. To further examine this potential overlap and to identify genes specifically involved in iRBD, we fully sequenced 25 genes previously identified in genome-wide association studies of Parkinson’s disease. The genes were captured and sequenced using targeted next-generation sequencing in a total of 1,039 iRBD patients and 1,852 controls of European ancestry. The role of rare heterozygous variants in these genes was examined using burden tests and optimized sequence Kernel association tests (SKAT-O), adjusted for age and sex. The contribution of biallelic (homozygous and compound heterozygous) variants was further tested in all genes. To examine the association of common variants in the target genes, we used logistic regression adjusted for age and sex. We found a significant association between rare heterozygous nonsynonymous variants in BST1 and iRBD ( p =0.0003 at coverage >50X and 0.0004 at >30X), mainly driven by three nonsynonymous variants (p.V85M, p.I101V and p.V272M) found in a total of 22 (1.2%) controls vs. two (0.2%) patients. Rare non-coding heterozygous variants in LAMP3 were also found to be associated with reduced iRBD risk ( p =0.0006 at >30X). We found no statistically significant association between rare heterozygous variants in the rest of genes and risk of iRBD. Several carriers of biallelic variants were identified, yet there was no overrepresentation in iRBD patients vs. controls. To examine the potential impact of the rare nonsynonymous BST1 variants on the protein structure, we performed in silico structural analysis. All three variants seem to be loss-of-function variants significantly affecting the protein structure and stability. Our results suggest that rare coding variants in BST1 and rare non-coding variants in LAMP3 are associated with iRBD, and additional studies are required to replicate these results and examine whether loss-of-function of BST1 could be a therapeutic target.
Open AccessNovel associations of BST1 and LAMP3 with rapid eye movement sleep behavior disorder
Isolated rapid-eye-movement (REM) sleep behavior disorder (iRBD) is a parasomnia, characterized by loss of muscle atonia and dream enactment occurring during REM sleep phase. Since a large subgroup of iRBD patients will convert to Parkinson’s disease, and since previous genetic studies have suggested common genes, it is likely that there is at least a partial overlap between iRBD and Parkinson’s disease genetics. To further examine this potential overlap and to identify genes specifically involved in iRBD, we fully sequenced 25 genes previously identified in genome-wide association studies of Parkinson’s disease. The genes were captured and sequenced using targeted next-generation sequencing in a total of 1,039 iRBD patients and 1,852 controls of European ancestry. The role of rare heterozygous variants in these genes was examined using burden tests and optimized sequence Kernel association tests (SKAT-O), adjusted for age and sex. The contribution of biallelic (homozygous and compound heterozygous) variants was further tested in all genes. To examine the association of common variants in the target genes, we used logistic regression adjusted for age and sex. We found a significant association between rare heterozygous nonsynonymous variants in BST1 and iRBD ( p =0.0003 at coverage >50X and 0.0004 at >30X), mainly driven by three nonsynonymous variants (p.V85M, p.I101V and p.V272M) found in a total of 22 (1.2%) controls vs. two (0.2%) patients. Rare non-coding heterozygous variants in LAMP3 were also found to be associated with reduced iRBD risk ( p =0.0006 at >30X). We found no statistically significant association between rare heterozygous variants in the rest of genes and risk of iRBD. Several carriers of biallelic variants were identified, yet there was no overrepresentation in iRBD patients vs. controls. To examine the potential impact of the rare nonsynonymous BST1 variants on the protein structure, we performed in silico structural analysis. All three variants seem to be loss-of-function variants significantly affecting the protein structure and stability. Our results suggest that rare coding variants in BST1 and rare non-coding variants in LAMP3 are associated with iRBD, and additional studies are required to replicate these results and examine whether loss-of-function of BST1 could be a therapeutic target.
- Open Access
A comprehensive analysis of dominant and recessive parkinsonism genes in REM sleep behavior disorder
Objective: To examine the role of autosomal dominant (AD) and recessive (AR) Parkinsonism genes in the risk of isolated rapid-eye-movement (REM) sleep behavior disorder (iRBD). Methods: Ten genes implicated in AD and AR Parkinsonism were fully sequenced using targeted next-generation sequencing in 1,039 iRBD patients and 1,852 controls of European ancestry. These include the AR genes PRKN, DJ-1 (PARK7), PINK1, VPS13C, ATP13A2, FBXO7 and PLA2G6 , and the AD genes LRRK2, GCH1 and VPS35 . To examine the role of rare heterozygous variants in these genes, burden test and SKAT-O analyses were performed. The contribution of homozygous and compound heterozygous variants was further examined in the AR genes. Copy number variants (CNVs) in PRKN were tested in a subset of samples (n=374) using multiplex ligation-dependent probe amplification followed by analysis of all samples using ExomeDepth. Results: We found no association between rare heterozygous variants in the tested genes and risk for iRBD. Several homozygous and compound heterozygous carriers were identified with variants of unknown significance, yet there was no overrepresentation in iRBD patients versus controls. Conclusion: Our results do not support a major role for variants in PRKN, PARK7, PINK1, VPS13C, ATP13A2, FBXO7, PLA2G6, LRRK2, GCH1 and VPS35 in the risk of iRBD.
Open AccessA comprehensive analysis of dominant and recessive parkinsonism genes in REM sleep behavior disorder
Objective: To examine the role of autosomal dominant (AD) and recessive (AR) Parkinsonism genes in the risk of isolated rapid-eye-movement (REM) sleep behavior disorder (iRBD). Methods: Ten genes implicated in AD and AR Parkinsonism were fully sequenced using targeted next-generation sequencing in 1,039 iRBD patients and 1,852 controls of European ancestry. These include the AR genes PRKN, DJ-1 (PARK7), PINK1, VPS13C, ATP13A2, FBXO7 and PLA2G6 , and the AD genes LRRK2, GCH1 and VPS35 . To examine the role of rare heterozygous variants in these genes, burden test and SKAT-O analyses were performed. The contribution of homozygous and compound heterozygous variants was further examined in the AR genes. Copy number variants (CNVs) in PRKN were tested in a subset of samples (n=374) using multiplex ligation-dependent probe amplification followed by analysis of all samples using ExomeDepth. Results: We found no association between rare heterozygous variants in the tested genes and risk for iRBD. Several homozygous and compound heterozygous carriers were identified with variants of unknown significance, yet there was no overrepresentation in iRBD patients versus controls. Conclusion: Our results do not support a major role for variants in PRKN, PARK7, PINK1, VPS13C, ATP13A2, FBXO7, PLA2G6, LRRK2, GCH1 and VPS35 in the risk of iRBD.
- Open Access
SMPD1 variants do not have a major role in REM sleep behavior disorder
Mutations in the sphingomyelin phosphodiesterase 1 ( SMPD1 ) gene were reported to be associated with Parkinson disease (PD) and dementia with Lewy bodies (DLB). The majority of patients with isolated rapid eye movement sleep behavior disorder (iRBD) develop PD or DLB later in life, suggesting that iRBD is a prodromal phase of these two conditions. In the current study we aimed to evaluate the role of SMPD1 variants in iRBD. SMPD1 and its untranslated regions were sequenced using targeted next-generation sequencing in 959 iRBD patients and 1,287 controls from European descent. Logistic regression adjusted for sex and age showed no significant associations with two common variants and iRBD (rs1050239 and rs8164). The frequency of all rare nonsynonymous SMPD1 variants (minor allele frequency p=0 . 09 ) but there was no statistically significant burden ( p=0 . 64 ). Our study reports no statistically significant association of SMPD1 variants and iRBD. It is hence unlikely that SMPD1 plays a major role in iRBD.
Open AccessSMPD1 variants do not have a major role in REM sleep behavior disorder
Mutations in the sphingomyelin phosphodiesterase 1 ( SMPD1 ) gene were reported to be associated with Parkinson disease (PD) and dementia with Lewy bodies (DLB). The majority of patients with isolated rapid eye movement sleep behavior disorder (iRBD) develop PD or DLB later in life, suggesting that iRBD is a prodromal phase of these two conditions. In the current study we aimed to evaluate the role of SMPD1 variants in iRBD. SMPD1 and its untranslated regions were sequenced using targeted next-generation sequencing in 959 iRBD patients and 1,287 controls from European descent. Logistic regression adjusted for sex and age showed no significant associations with two common variants and iRBD (rs1050239 and rs8164). The frequency of all rare nonsynonymous SMPD1 variants (minor allele frequency p=0 . 09 ) but there was no statistically significant burden ( p=0 . 64 ). Our study reports no statistically significant association of SMPD1 variants and iRBD. It is hence unlikely that SMPD1 plays a major role in iRBD.
- Open Access
GBA variants in REM sleep behavior disorder: a multicenter study
Objective: To study the role of GBA variants in the risk for isolated rapid-eye-movement (REM)-sleep behavior disorder (iRBD) and conversion to overt neurodegeneration. Methods: A total of 4,147 individuals were included: 1,061 iRBD patients and 3,086 controls. GBA was fully sequenced using molecular inversion probes and Sanger sequencing. We analyzed the effects of GBA variants on the risk for iRBD, age at onset (AAO) and conversion rates. Results: GBA variants were found in 9.5% of iRBD patients compared to 4.1% in controls (odds ratio [OR]=2.45, 95% CI=1.87–3.22, p =1×10 −10 ). The estimated OR for mild p.N370S variant carriers was 3.69, 95% CI=1.90–7.14, p =3.5×10 −5 , while for severe variant carriers it was 17.55, 95% CI=2.11–145.9, p =0.0015. Carriers of severe GBA variants had an average AAO of 52.8 years, 7-8 years earlier than those with mild variants or non-carriers ( p =0.029). Of the GBA variant carriers with available data, 52.5% had converted, compared to 35.6% in non-carriers ( p =0.011), with a trend for faster conversion among severe GBA variant carriers. However, the results on AAO and conversion were based on small numbers and should be taken with caution. Conclusions: GBA variants robustly and differentially increase the risk of iRBD. The rate of conversion to neurodegeneration is also increased and may be faster among severe GBA variant carriers, although confirmation will be required in larger samples. Screening for RBD in healthy carriers of GBA variants should be studied as a potential way to identify GBA variant carriers who will develop a synucleinopathy in the future.
Open AccessGBA variants in REM sleep behavior disorder: a multicenter study
Objective: To study the role of GBA variants in the risk for isolated rapid-eye-movement (REM)-sleep behavior disorder (iRBD) and conversion to overt neurodegeneration. Methods: A total of 4,147 individuals were included: 1,061 iRBD patients and 3,086 controls. GBA was fully sequenced using molecular inversion probes and Sanger sequencing. We analyzed the effects of GBA variants on the risk for iRBD, age at onset (AAO) and conversion rates. Results: GBA variants were found in 9.5% of iRBD patients compared to 4.1% in controls (odds ratio [OR]=2.45, 95% CI=1.87–3.22, p =1×10 −10 ). The estimated OR for mild p.N370S variant carriers was 3.69, 95% CI=1.90–7.14, p =3.5×10 −5 , while for severe variant carriers it was 17.55, 95% CI=2.11–145.9, p =0.0015. Carriers of severe GBA variants had an average AAO of 52.8 years, 7-8 years earlier than those with mild variants or non-carriers ( p =0.029). Of the GBA variant carriers with available data, 52.5% had converted, compared to 35.6% in non-carriers ( p =0.011), with a trend for faster conversion among severe GBA variant carriers. However, the results on AAO and conversion were based on small numbers and should be taken with caution. Conclusions: GBA variants robustly and differentially increase the risk of iRBD. The rate of conversion to neurodegeneration is also increased and may be faster among severe GBA variant carriers, although confirmation will be required in larger samples. Screening for RBD in healthy carriers of GBA variants should be studied as a potential way to identify GBA variant carriers who will develop a synucleinopathy in the future.
- Open Access
Fine-mapping of SNCA in REM sleep behavior disorder and overt synucleinopathies
Objective: REM-sleep behavior disorder (RBD) is a prodromal synucleinopathy, as >80% will eventually convert to overt synucleinopathy. We performed an in-depth analysis of the SNCA locus to identify RBD-specific risk variants. Methods: Full sequencing and genotyping of SNCA was performed in isolated/idiopathic RBD (iRBD, n=1,076), Parkinson’s disease (PD, n=1,013), and dementia with Lewy bodies (DLB, n=415), and in control subjects (n=6,155). A replication cohort from 23andMe of PD patients with probable RBD (pRBD) was also analyzed (cases n=1,782, controls n=131,250). Adjusted logistic regression models and meta-analyses were performed. Effects on conversion rate were analyzed in 432 RBD patients with available data using Kaplan-Meier survival analysis. Results: A 5’-region SNCA variant (rs10005233) was associated with iRBD (OR=1.43, p =1.1E-08), which was replicated in pRBD. This variant is in linkage disequilibrium (LD) with other 5’ risk variants across the different synucleinopathies. An independent iRBD-specific suggestive association (rs11732740) was detected at the 3’ of SNCA (OR=1.32, p =4.7E-04, not statistically significant after Bonferroni correction). Homozygous carriers of both iRBD-specific SNPs were at highly increased risk for iRBD (OR=5.74, p =2E-06). The known top PD-associated variant (3’ variant rs356182) had an opposite direction of effect in iRBD compared to PD. Interpretation: There is a distinct pattern of association at the SNCA locus in RBD as compared to PD, with an opposite direction of effect at the 3’ of SNCA . Several 5’ SNCA variants are associated with iRBD and with pRBD in overt synucleinopathies, and may suggest a cognitive component to this region.
Open AccessFine-mapping of SNCA in REM sleep behavior disorder and overt synucleinopathies
Objective: REM-sleep behavior disorder (RBD) is a prodromal synucleinopathy, as >80% will eventually convert to overt synucleinopathy. We performed an in-depth analysis of the SNCA locus to identify RBD-specific risk variants. Methods: Full sequencing and genotyping of SNCA was performed in isolated/idiopathic RBD (iRBD, n=1,076), Parkinson’s disease (PD, n=1,013), and dementia with Lewy bodies (DLB, n=415), and in control subjects (n=6,155). A replication cohort from 23andMe of PD patients with probable RBD (pRBD) was also analyzed (cases n=1,782, controls n=131,250). Adjusted logistic regression models and meta-analyses were performed. Effects on conversion rate were analyzed in 432 RBD patients with available data using Kaplan-Meier survival analysis. Results: A 5’-region SNCA variant (rs10005233) was associated with iRBD (OR=1.43, p =1.1E-08), which was replicated in pRBD. This variant is in linkage disequilibrium (LD) with other 5’ risk variants across the different synucleinopathies. An independent iRBD-specific suggestive association (rs11732740) was detected at the 3’ of SNCA (OR=1.32, p =4.7E-04, not statistically significant after Bonferroni correction). Homozygous carriers of both iRBD-specific SNPs were at highly increased risk for iRBD (OR=5.74, p =2E-06). The known top PD-associated variant (3’ variant rs356182) had an opposite direction of effect in iRBD compared to PD. Interpretation: There is a distinct pattern of association at the SNCA locus in RBD as compared to PD, with an opposite direction of effect at the 3’ of SNCA . Several 5’ SNCA variants are associated with iRBD and with pRBD in overt synucleinopathies, and may suggest a cognitive component to this region.
- 19 September 2018
- Published by Springer Nature
- p. 53-65
REM Sleep Behavior Disorder Associated with Parkinson’s Disease and Multiple System Atrophy
- 19 September 2018
- Published by Springer Nature
- p. 53-65
REM Sleep Behavior Disorder Associated with Parkinson’s Disease and Multiple System Atrophy
- 1 September 2017
- Published by Springer Nature in DNP - Der Neurologe und Psychiater
- Vol. 18 (1) , 45-50
Praktische Tipps zur Eskalationstherapie des Morbus Parkinson
- 1 September 2017
- Published by Springer Nature in DNP - Der Neurologe und Psychiater
- Vol. 18 (1) , 45-50
Praktische Tipps zur Eskalationstherapie des Morbus Parkinson
- 23 November 2016
- Published by Georg Thieme Verlag KG in Aktuelle Neurologie
- Vol. 43 (09) , 559-567
Invasive Therapien bei fortgeschrittener Parkinson-Krankheit: Was wann für wen?
Neben der herkömmlichen Pharmakotherapie haben sich in den letzten Jahren 3 nicht orale Therapiemethoden bei der Parkinson-Krankheit etabliert. Diese sind in Erwägung zu ziehen, wenn aufgrund von motorischen Fluktuationen oder Unverträglichkeiten mit ausschließlich oraler und/oder transdermaler Pharmakotherapie keine stabile motorische Verfügbarkeit im Tagesverlauf mehr gesichert werden kann. Apomorphin zur subkutanen Applikation als Einmalinjektion oder zur kontinuierlichen subkutanen Infusion stellt die am wenigsten invasive Option dar, ist deren Anpassung doch nicht mit einer Operation verbunden. Als potentester Dopaminagonist ist Apomorphin jedoch grundsätzlich mit dem typischen Risiko- und Nebenwirkungsprofil dieser Substanzklasse, wie z. B. Psychosen und Impulskontrollstörungen, verbunden. Die kontinuierliche intrajejunale Instillation von Levodopa über eine Pumpe empfiehlt sich als Alternative für die Patienten, die eine Apomorphintherapie nicht (mehr) tolerieren oder die durch zusätzliche Schluckstörungen ohnehin zur Sicherung der Ernährungssituation und weiterer Medikamentengaben eine Ernährungssonde benötigen. Da diese Therapie mit der Anlage einer perkutanen endoskopischen Gastrojejunostomie (PEG/PEJ) verbunden ist, hat sie eine höhere Invasivität als die Apomorphintherapie. Die Vorteile liegen in der Substanz Levodopa als Monotherapie. Dies ist vor allem für ältere Parkinson-Patienten mit kognitiven Defiziten und Psychoserisiko sowie den o. g. Schluckstörungen von Vorteil. Insbesondere für jüngere, kognitiv intakte Betroffene, die das Stigma und die körperlichen Einschränkungen durch eine Pumpe scheuen, bietet sich die tiefe Hirnstimulation als Alternative an. Für diese invasivste der hier vorgestellten Therapien gelten sorgfältig zu beachtende Ein- und Ausschlusskriterien. Als einzige der 3 hier vorgestellten Methoden gibt es für diese Therapie eine evidenzbasierte Empfehlung zum Einsatz in frühen bis mittleren Krankheitsphasen bei nicht dementen Patienten sobald Fluktuationen auftreten. Die THS-Indikation ist begrenzt durch ein Alter über 70 und Levodopa-resistente Störungen. Für alle 3 Therapien gilt, dass sowohl die Anpassung als auch die Überwachung von diesbezüglich erfahrenen Ärzten geleistet werden sollte. Over the past years three invasive therapies have become available for patients with advanced Parkinson’s disease (PD), when conventional pharmacotherapy can no longer guarantee stable motor performance. Subcutaneous injections or continuous infusions of apomorphine are the least invasive of the three methods presented here as there is no need for an operation to implement this therapy. Being a dopamine agonist, apomorphine is not a suitable therapy for patients with a history of psychosis or compulsive obsessive behaviours. Continuous intrajejunal instillation of levodopa may be an alternative for those who do not tolerate apomorphine. The implementation of the percutaneous endoscopic jejunostomy (PEJ), however, requires an operation. The advantage is that levodopa is a monotherapy and gives the patient independence from additional Parkinson medication during the day. For younger patients, deep brain stimulation of the subthalamic nucleus is a well-investigated and approved alternative. Careful preoperative evaluation with strict adherence to inclusion and exclusion criteria is mandatory for this most invasive of therapies. According to recent data, deep brain stimulation may be recommended in earlier and moderately severe stages of the disease when fluctuations have just begun. On the other hand, limitations due to age and levodopa-resistant symptoms need to be considered. All three invasive therapies should be implemented and supervised only by specialized physicians.
- 23 November 2016
- Published by Georg Thieme Verlag KG in Aktuelle Neurologie
- Vol. 43 (09) , 559-567
Invasive Therapien bei fortgeschrittener Parkinson-Krankheit: Was wann für wen?
Neben der herkömmlichen Pharmakotherapie haben sich in den letzten Jahren 3 nicht orale Therapiemethoden bei der Parkinson-Krankheit etabliert. Diese sind in Erwägung zu ziehen, wenn aufgrund von motorischen Fluktuationen oder Unverträglichkeiten mit ausschließlich oraler und/oder transdermaler Pharmakotherapie keine stabile motorische Verfügbarkeit im Tagesverlauf mehr gesichert werden kann. Apomorphin zur subkutanen Applikation als Einmalinjektion oder zur kontinuierlichen subkutanen Infusion stellt die am wenigsten invasive Option dar, ist deren Anpassung doch nicht mit einer Operation verbunden. Als potentester Dopaminagonist ist Apomorphin jedoch grundsätzlich mit dem typischen Risiko- und Nebenwirkungsprofil dieser Substanzklasse, wie z. B. Psychosen und Impulskontrollstörungen, verbunden. Die kontinuierliche intrajejunale Instillation von Levodopa über eine Pumpe empfiehlt sich als Alternative für die Patienten, die eine Apomorphintherapie nicht (mehr) tolerieren oder die durch zusätzliche Schluckstörungen ohnehin zur Sicherung der Ernährungssituation und weiterer Medikamentengaben eine Ernährungssonde benötigen. Da diese Therapie mit der Anlage einer perkutanen endoskopischen Gastrojejunostomie (PEG/PEJ) verbunden ist, hat sie eine höhere Invasivität als die Apomorphintherapie. Die Vorteile liegen in der Substanz Levodopa als Monotherapie. Dies ist vor allem für ältere Parkinson-Patienten mit kognitiven Defiziten und Psychoserisiko sowie den o. g. Schluckstörungen von Vorteil. Insbesondere für jüngere, kognitiv intakte Betroffene, die das Stigma und die körperlichen Einschränkungen durch eine Pumpe scheuen, bietet sich die tiefe Hirnstimulation als Alternative an. Für diese invasivste der hier vorgestellten Therapien gelten sorgfältig zu beachtende Ein- und Ausschlusskriterien. Als einzige der 3 hier vorgestellten Methoden gibt es für diese Therapie eine evidenzbasierte Empfehlung zum Einsatz in frühen bis mittleren Krankheitsphasen bei nicht dementen Patienten sobald Fluktuationen auftreten. Die THS-Indikation ist begrenzt durch ein Alter über 70 und Levodopa-resistente Störungen. Für alle 3 Therapien gilt, dass sowohl die Anpassung als auch die Überwachung von diesbezüglich erfahrenen Ärzten geleistet werden sollte. Over the past years three invasive therapies have become available for patients with advanced Parkinson’s disease (PD), when conventional pharmacotherapy can no longer guarantee stable motor performance. Subcutaneous injections or continuous infusions of apomorphine are the least invasive of the three methods presented here as there is no need for an operation to implement this therapy. Being a dopamine agonist, apomorphine is not a suitable therapy for patients with a history of psychosis or compulsive obsessive behaviours. Continuous intrajejunal instillation of levodopa may be an alternative for those who do not tolerate apomorphine. The implementation of the percutaneous endoscopic jejunostomy (PEJ), however, requires an operation. The advantage is that levodopa is a monotherapy and gives the patient independence from additional Parkinson medication during the day. For younger patients, deep brain stimulation of the subthalamic nucleus is a well-investigated and approved alternative. Careful preoperative evaluation with strict adherence to inclusion and exclusion criteria is mandatory for this most invasive of therapies. According to recent data, deep brain stimulation may be recommended in earlier and moderately severe stages of the disease when fluctuations have just begun. On the other hand, limitations due to age and levodopa-resistant symptoms need to be considered. All three invasive therapies should be implemented and supervised only by specialized physicians.
- Open Access
- 8 November 2016
- Published by Springer Nature in BMC Neurology
- Vol. 16 (1) , 1-4
Asphyxia due to laryngeal spasm as a severe complication of awake deep brain stimulation for Parkinson’s disease: a case report
In accordance with German neurosurgical and neurological consensus recommendations, lead placements for deep brain stimulation (DBS) in patients with Parkinson’s disease (PD) are usually performed with the patient awake and in “medication off” state. This allows for optimal lead position adjustment according to the clinical response to intraoperative test stimulation. However, exacerbation of Parkinsonian symptoms after withdrawal of dopaminergic medication may endanger the patient by inducing severe “off” state motor phenomena. In particular, this can be a problem in awake craniotomies utilizing intraoperative airway management and resuscitation. We report the case of a PD patient with progressive orofacial and neck muscle dystonia resulting in laryngeal spasm during DBS lead placement. This led to upper airway compromise and asphyxia, requiring resuscitation. Laryngeal spasms may occur as a rare “off” state motor complication in patients with PD. Other potential causes of intraoperative difficulties breathing include bilateral vocal cord palsy, positional asphyxia, and silent aspiration. In our practice, we have adjusted our medication regimen and now allow patients to receive their standard dopaminergic medication until the morning of surgery. Neurologists and neurosurgeons performing lead placement procedures for PD should be aware of this rare but unsafe condition to most optimized treatment.
- 8 November 2016
- Published by Springer Nature in BMC Neurology
- Vol. 16 (1) , 1-4
Open AccessAsphyxia due to laryngeal spasm as a severe complication of awake deep brain stimulation for Parkinson’s disease: a case report
In accordance with German neurosurgical and neurological consensus recommendations, lead placements for deep brain stimulation (DBS) in patients with Parkinson’s disease (PD) are usually performed with the patient awake and in “medication off” state. This allows for optimal lead position adjustment according to the clinical response to intraoperative test stimulation. However, exacerbation of Parkinsonian symptoms after withdrawal of dopaminergic medication may endanger the patient by inducing severe “off” state motor phenomena. In particular, this can be a problem in awake craniotomies utilizing intraoperative airway management and resuscitation. We report the case of a PD patient with progressive orofacial and neck muscle dystonia resulting in laryngeal spasm during DBS lead placement. This led to upper airway compromise and asphyxia, requiring resuscitation. Laryngeal spasms may occur as a rare “off” state motor complication in patients with PD. Other potential causes of intraoperative difficulties breathing include bilateral vocal cord palsy, positional asphyxia, and silent aspiration. In our practice, we have adjusted our medication regimen and now allow patients to receive their standard dopaminergic medication until the morning of surgery. Neurologists and neurosurgeons performing lead placement procedures for PD should be aware of this rare but unsafe condition to most optimized treatment.